ZG006 Ignites T‑Cell Response in Refractory SCLC by Targeting DLL3

ZG006 is a unique designed T cell engager, targeting CD3 and Delta-like ligand 3 (DLL3) on DLL3-expressing tumor cells such as small cell lung cancer (SCLC) or neuroendocrine carcinoma (NEC). In the phase 1 study with 45 patients (23 evaluable), ZG006 monotherapy achieved a 60.9% ORR (with 66.7% ORR in low/medium DLL3 expressors) and 78.3% DCR in SCLC/NEC, with manageable cytokine release syndrome and a single DLT at 100 mg; drug exposure increased nearly dose-proportionally with a ~4‑day half‐life. Eleven pts (24.4%) experienced serious TRAEs with no discontinuations for AEs.